: iStockAnalyst.com Symbols Feed

Analyst Comments: Philips, Cepheid, National Semi, Heritage-Crystal, Primus Guaranty, Reddy Ice, BioSphere, PS Business Parks, ArvinMeritor, Bristol-Myers, Echelon, LSI Corp

Fri, 03 Oct 2008 06:18:00 GMT

Headquartered in Amsterdam, The Netherlands, Koninklijke Philips Electronics N.V. (PHG) is one of the world's largest electronics companies and the biggest in Europe, with sales of 27 billion in 2007 and 12.4 billion in 1H08. The company has worked to improve its cost structure, as its EBITA margins remained flat along with modest revenue performance despite the weaker-than-expected dollar. Based on these results, we are maintaining our revenue estimates for 2008. We continue to rate the shares of PHG a Hold with a price target of $28.50 per share over the next six months. This amounts to between 6.7x-6.9x our new 2008 EPS estimate of $4.19. Udayan Mukherjee contributed to this report. Read[More...]

Be Selective with Medical Devices

Wed, 06 Aug 2008 18:30:00 GMT

With earnings season beginning to wind down in the medical devices and supplies industry, we figured it would be a good time to check in with Zacks senior analyst Tom Park. We were looking to see if there are any attractive buys among his coverage. What was the last research report you issued, and what was your rating on the company? Cepheid (CPHD) is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical molecular diagnostic, industrial, and biothreat markets. We currently rate shares of Cepheid a Hold. CPHD reported Q2 EPS that were lower[More...]

Analyst Comments: Trimble Navigation, Cepheid, Ball Corporation, Cleveland-Cliff

Mon, 14 Jul 2008 23:18:00 GMT

Trimble Navigation, Ltd. (TRMB) is an original equipment manufacturer (OEM) of GPS-based products and control systems. Both revenue and EPS exceeded the consensus in the March quarter. Revenue growth was the strongest in the TFS segment, driven by continued momentum in the ag market. Operating margins expanded in all except the E&C segment. Forward guidance is for a 5-6% sequential increase in...[More...]

Accumulating Paper

Tue, 08 Jul 2008 18:29:00 GMT

As Promised, I am delivering a copious portion of ticker symbols that were exported from a bullish scan I just performed. The results were pretty decent, and there is plenty to look over (I have visually...[More...]

Cepheid: The Next Generation of Diagnostics

Mon, 07 Jul 2008 13:45:00 GMT

"I still love Cepheid (NASDAQ: CPHD)," says biotechnology sector expert Michael Shulman in his always-fascinating ChangeWave Biotech Investor.[More...]

Cashing Out On Oil, Up Goes The Qs!

Fri, 30 May 2008 06:11:23 GMT

The market was solid today; thanks to a favorable GDP report and declining oil prices. Commodities and energy plays, including the solars, were weak. Techs were strong, as QQQQ (the Qs) went back to nearly $50. Financials also showed strength today, helpe[More...]

NASDAQ Technical Picture - Expansion

Fri, 02 May 2008 05:56:25 GMT

The only thi[More...]

FOMC Takes Centre Stage This Week

Tue, 29 Apr 2008 00:08:41 GMT

The market is in a critical junction now. S&P 500 is near 1,400 level, which is an important resistance level. If you can break and follow through, there is a good chance of uptrend continuing. Let's see how the market reacts this Wed on FOMC statement.[More...]

Hump Day

Wed, 12 Mar 2008 14:15:43 GMT

Good morning. As everyone tries to figure out how effective the latest action by the Fed will affect the credit markets and economy, premarket futures are pointing to a lower open.[More...]

Action & Reaction

Thu, 21 Feb 2008 12:55:41 GMT

The stock market started weak after more than concerning numbers in the CPI and bearish commentary from the Fed. But despite these...[More...]

Cepheid to Webcast Upcoming Financial Presentations

Wed, 26 Aug 2009 10:56:00 GMT

Cepheid today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast.[More...]

Cepheid Reports 2009 Second Quarter Results

Thu, 30 Jul 2009 19:56:00 GMT

Cepheid today reported revenue for the second quarter of 2009 of $41.0 million. Net loss was $6.8 million, or $ per share, which compares to revenue of $42.1 million and a net loss of $7.7 million, or $ per share, in the second quarter of 2008.[More...]

BenchmarkJournal.Com Free Analyst Review for SWHC, AMAT, SYNA, VRTX, CPHD and AKAM

Mon, 13 Jul 2009 14:14:00 GMT

Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities.
Today we began research on Smith & Wesson Holding Corp. (NASDAQ: SWHC), Applied Materials Inc. (NASDAQ: AMAT), Synaptics Inc. (NASDAQ: SYNA), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Cepheid (NASDAQ: CPHD) and Akamai Technologies Inc. (NASDAQ: AKAM).
To view our research, sign up now and get started with your complimentary subscription.

[More...]

Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection

Mon, 13 Jul 2009 10:56:00 GMT

Cepheid today announced it has received clearance from the U.S. Food & Drug Administration to market its Xpert C. difficile test, an on-demand molecular diagnostic test designed for 45-minute detection of the bacterium that causes Clostridium difficile infection . The Xpert C. difficile test is the first test for CDI to deliver both rapid turnaround and a high degree of accuracy.[More...]

Cepheid Schedules 2009 Second Quarter Financial Results Announcement and Webcast

Thu, 09 Jul 2009 10:56:00 GMT

Cepheid today announced that it will report financial results for its second quarter ended June 30, 2009, on Thursday, July 30, 2009, after the close of the market.[More...]

New England Journal of Medicine Study Highlights Need for Rapid, PCR-based Group B Streptococcus (GBS) Testing at Time of Admission for Labor and Delivery

Wed, 24 Jun 2009 10:56:00 GMT

Cepheid today noted that a new article, Evaluation of Universal Antenatal Screening for Group B Streptococcus, published in the June 2009 issue of the New England Journal of Medicine concluded that rapid, PCR-based testing at the time of admission for delivery may improve the accuracy of Group B streptococcal screening over the normal antepartum testing done at 35-37 weeks of gestation.[More...]

Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)

Wed, 17 Jun 2009 10:56:00 GMT

Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)[More...]

Cepheid Receives Grant to Develop Ten-Color Real-Time PCR Detection Technology for Use in the GeneXpert(R) System

Wed, 10 Jun 2009 10:55:00 GMT

New Capabilities Will Further Extend GeneXpert System Technology Advantages[More...]

Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference

Thu, 04 Jun 2009 10:55:00 GMT

- Cepheid today announced speaker and program highlights for its symposium, "On-Demand HAI Testing: Good Medicine and Good Business," which the company will host at the 2009 Association for Professionals in Infection Control annual conference, taking place in Fort Lauderdale, Florida, June 7th - 10th. Cepheid's GeneXpert Systems and menu of molecular diagnostic tests will be on display in booth #906 on the exhibition floor.[More...]